Literature DB >> 7537325

Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes.

P Heino1, B Skyldberg, M Lehtinen, I Rantala, B Hagmar, J W Kreider, R Kirnbauer, J Dillner.   

Abstract

The study of viral infectivity and detection of viral capsid antigens of the major cervical cancer-associated human papillomavirus (HPV) type, HPV-16, requires knowledge of which epitopes are exposed in clinical specimens of infected tissue or on intact capsids. To define the antigenic epitopes of HPV-16, antisera to 66 overlapping synthetic peptides corresponding to the HPV-16 capsid proteins L1 and L2 and to seven peptide analogues were tested in immunoperoxidase stainings of consecutive sections from formalin-fixed, paraffin-embedded HPV infected tissue. Antisera against eleven different peptides from L1 and against seven different peptides from L2 recognized the HPV capsid antigen. Most epitopes were only found on the capsid antigen of certain genital HPV types, but four antigenic epitopes in L1 were detectable also in cutaneous wart specimens. All antigenic epitopes in L2 were restricted to genital HPV types and four L2 epitopes were only detectable in HPV-16 or HPV-33 positive specimens. The surface exposure of the antigenic epitopes was investigated by comparing the reactivity of the antipeptide antisera with intact or disrupted virions or capsids of HPV-11, HPV-16 and bovine papillomavirus (BPV). Twenty antipeptide sera from L1 and seven antipeptide sera from L2 were reactive with intact HPV-16 capsids at titres up to 1:146,000. Sixteen of these antisera were also reactive with disrupted HPV-16 capsids. Cross-reactivity with disrupted HPV-11 and BPV was detected for eleven and six antisera, respectively, whereas intact HPV-11 or BPV virions showed only weak cross-reactivity. In conclusion, the HPV-16 L1 and L2 capsid proteins contained multiple antigenic epitopes, most of which were shared with one or several additional HPV types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537325     DOI: 10.1099/0022-1317-76-5-1141

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

3.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

4.  Cell surface-binding motifs of L2 that facilitate papillomavirus infection.

Authors:  Rongcun Yang; Patricia M Day; William H Yutzy; Ken-Yu Lin; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.

Authors:  M M Okun; P M Day; H L Greenstone; F P Booy; D R Lowy; J T Schiller; R B Roden
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 6.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

7.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.

Authors:  S W Ludmerer; D Benincasa; G E Mark; N D Christensen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein.

Authors:  Elizabeth Webb; John Cox; Stirling Edwards
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.